| 24613930 |
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
Kelly, LM,
Barila, G,
Liu, P,
Evdokimova, VN,
Trivedi, S,
Panebianco, F,
Gandhi, M,
Carty, SE,
Hodak, SP,
Luo, J,
Dacic, S,
Yu, YP,
Nikiforova, MN,
Ferris, RL,
Altschuler, DL,
Nikiforov, YE
|
Proc Natl Acad Sci U S A |
2014 |
| 28404650 |
Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient
Tian, Q,
Deng, WJ,
Li, ZW
|
Eur Respir J |
2017 |
| 26301689 |
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Hrustanovic, G,
Olivas, V,
Pazarentzos, E,
Tulpule, A,
Asthana, S,
Blakely, CM,
Okimoto, RA,
Lin, L,
Neel, DS,
Sabnis, A,
Flanagan, J,
Chan, E,
Varella-Garcia, M,
Aisner, DL,
Vaishnavi, A,
Ou, SH,
Collisson, EA,
Ichihara, E,
Mack, PC,
Lovly, CM,
Karachaliou, N,
Rosell, R,
Riess, JW,
Doebele, RC,
Bivona, TG
|
Nat Med |
2015 |
| 22570254 |
Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer
Ren, H,
Tan, ZP,
Zhu, X,
Crosby, K,
Haack, H,
Ren, JM,
Beausoleil, S,
Moritz, A,
Innocenti, G,
Rush, J,
Zhang, Y,
Zhou, XM,
Gu, TL,
Yang, YF,
Comb, MJ
|
Cancer Res |
2012 |
| 24496003 |
HIP1-ALK, a novel ALK fusion variant that responds to crizotinib
Fang, DD,
Zhang, B,
Gu, Q,
Lira, M,
Xu, Q,
Sun, H,
Qian, M,
Sheng, W,
Ozeck, M,
Wang, Z,
Zhang, C,
Chen, X,
Chen, KX,
Li, J,
Chen, SH,
Christensen, J,
Mao, M,
Chan, CC
|
J Thorac Oncol |
2014 |
| 20979473 |
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
Choi, YL,
Soda, M,
Yamashita, Y,
Ueno, T,
Takashima, J,
Nakajima, T,
Yatabe, Y,
Takeuchi, K,
Hamada, T,
Haruta, H,
Ishikawa, Y,
Kimura, H,
Mitsudomi, T,
Tanio, Y,
Mano, H,
ALK Lung Cancer Study Group, -
|
N. Engl. J. Med. |
2010 |
| 27245569 |
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization
Ali, SM,
Hensing, T,
Schrock, AB,
Allen, J,
Sanford, E,
Gowen, K,
Kulkarni, A,
He, J,
Suh, JH,
Lipson, D,
Elvin, JA,
Yelensky, R,
Chalmers, Z,
Chmielecki, J,
Peled, N,
Klempner, SJ,
Firozvi, K,
Frampton, GM,
Molina, JR,
Menon, S,
Brahmer, JR,
MacMahon, H,
Nowak, J,
Ou, SH,
Zauderer, M,
Ladanyi, M,
Zakowski, M,
Fischbach, N,
Ross, JS,
Stephens, PJ,
Miller, VA,
Wakelee, H,
Ganesan, S,
Salgia, R
|
Oncologist |
2016 |
| 25393796 |
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib
Ou, SH,
Klempner, SJ,
Greenbowe, JR,
Azada, M,
Schrock, AB,
Ali, SM,
Ross, JS,
Stephens, PJ,
Miller, VA
|
J Thorac Oncol |
2014 |
| 25421750 |
Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma
Ceccon, M,
Mologni, L,
Giudici, G,
Piazza, R,
Pirola, A,
Fontana, D,
Gambacorti-Passerini, C
|
Mol. Cancer Res. |
2015 |
| 26001147 |
BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib
Shan, L,
Jiang, P,
Xu, F,
Zhang, W,
Guo, L,
Wu, J,
Zeng, Y,
Jiao, Y,
Ying, J
|
J Thorac Oncol |
2015 |
| 32573700 |
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma
Prokoph, N,
Probst, NA,
Lee, LC,
Monahan, JM,
Matthews, JD,
Liang, HC,
Bahnsen, K,
Montes-Mojarro, IA,
Karaca-Atabay, E,
Sharma, GG,
Malik, V,
Larose, H,
Forde, SD,
Ducray, SP,
Lobello, C,
Wang, Q,
Luan, SL,
Pospisilova, S,
Gambacorti-Passerini, C,
Burke, GAA,
Pervez, S,
Attarbaschi, A,
Janíková, A,
Pacquement, H,
Landman-Parker, J,
Lambilliotte, A,
Schleiermacher, G,
Klapper, W,
Jauch, R,
Woessmann, W,
Vassal, G,
Kenner, L,
Merkel, O,
Mologni, L,
Chiarle, R,
Brugières, L,
Geoerger, B,
Barbieri, I,
Turner, SD
|
Blood |
2020 |
| 24518094 |
HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma
Hong, M,
Kim, RN,
Song, JY,
Choi, SJ,
Oh, E,
Lira, ME,
Mao, M,
Takeuchi, K,
Han, J,
Kim, J,
Choi, YL
|
J Thorac Oncol |
2014 |
| 31388026 |
Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity
Chuang, YC,
Huang, BY,
Chang, HW,
Yang, CN
|
Sci Rep |
2019 |
| 21502504 |
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Katayama, R,
Khan, TM,
Benes, C,
Lifshits, E,
Ebi, H,
Rivera, VM,
Shakespeare, WC,
Iafrate, AJ,
Engelman, JA,
Shaw, AT
|
Proc. Natl. Acad. Sci. U.S.A. |
2011 |
